Synthszr Charts — die großen AI-Marken im Wettkampf ums Podium

Oracle Health

Oracle · 2× · tolest 21. Aug. 2026

Momentum

Oracle Health Clinical AI Agent is an AI-powered clinical assistant integrated into the Oracle Health EHR (Millennium platform) that supports physicians with documentation, coding, and chart review. In August 2026, new features for automated Professional Fee Coding, clinician-controlled real-time dictation, and AI-powered Chart Review were launched in the US. The system is based on a multi-agent architecture with semantic Reasoning that enables various AI agents to collaborate, understand clinical significance, and automate workflows while keeping control with the clinician. According to Oracle, the note-generation feature alone has already saved over 400,000 hours across US healthcare organizations.

Momentum-Verloop

25.05.23.08.

Features

Compliance/Certification	Listed on NHS England's registry of approved Ambient Voice Technology (AVT) suppliers meeting NHS standards
Deployment Model	Cloud-based on Oracle Cloud Infrastructure (OCI), available as a standalone feature that can work with any EHR
Use Case Scope	Ambulatory, inpatient and emergency department care, more than 30 medical specialty areas (e.g. cardiology, nephrology, urology, behavioral health)
Integrations	Directly integrated with Oracle Health EHR/Millennium platform; multi-agent system for order creation, coding, dictation and chart review
Platform	Based on the Oracle Digital Assistant platform, integrated into Oracle Health EHR (Millennium), runs on Oracle Cloud Infrastructure (OCI)
Price	Not publicly listed; custom quote per healthcare organization
Release Date	October 29, 2024 (2nd generation); new coding/dictation/chart review features: August 19, 2026 (U.S.)

Mehr Produkten in disse Kategorie: KI in't Gesundheitswesen

Belege (2)

Company Analysis: Oracle

As of 22/08/2026

HOLDSynthszr Vote

Oracle’s fundamentals show strong cloud momentum and unusually high contracted-demand visibility (RPO $638B, +363% YoY) alongside improving operating income. (investor.oracle.com) However, the FY2026 cash flow profile is the binding constraint: free cash flow was -$23.7B driven by $55.7B of capex for data center expansion. (d18rn0p25nwr6d.cloudfront.net) With the current price unspecified and valuation inputs varying by vendor, a data-driven stance is to HOLD until there is clearer evidence that (1) OCI capacity additions convert backlog into recognized revenue on schedule and (2) capex intensity begins to normalize, allowing FCF to inflect toward sustainably positive levels.

Summary

Oracle Corporation is a diversified enterprise software and cloud services provider with three primary economic engines: (1) Cloud Infrastructure (OCI) for compute/storage/networking and AI training/inference capacity, (2) Cloud Applications (Fusion, NetSuite, Cerner/health, and industry suites) sold largely as subscription SaaS, and (3) a large installed base of database and middleware customers that still generates high-margin support revenue and provides a conversion funnel into Oracle Cloud and “bring-your-own-license” deployments. Oracle’s core competencies remain database performance/reliability, mission-critical enterprise workflows, and increasingly, high-throughput infrastructure for AI workloads. Market position has improved materially in cloud infrastructure visibility, driven by large multi-year commitments and a sharp expansion in Remaining Performance Obligations (RPO). In Q4 FY2026, Oracle reported RPO of $638B (+363% YoY), indicating unusually high contracted demand and long-duration commitments relative to its current revenue base. (investor.oracle.com) Management also guided for very strong near-term cloud growth (total cloud revenue expected to grow ~57%–63% in constant currency, ~58%–64% in USD for the next period referenced in the release), reinforcing momentum in OCI and cloud applications. (oracle.com) Operating leverage is visible at the income statement level (Q4 GAAP operating income +20%; non-GAAP operating income +22% to a record $8.6B), but the cash flow profile is currently dominated by infrastructure build-out. (investor.oracle.com) The key financial tension is that Oracle is converting demand into backlog faster than it can convert backlog into delivered capacity. Fiscal 2026 free cash flow was -$23.7B, primarily due to capex rising to $55.7B as Oracle expanded data centers for OCI growth. (oracle.com) This makes valuation and risk assessment unusually sensitive to execution (capacity delivery, pricing, utilization) and funding (debt/equity mix). Valuation metrics vary by data vendor, but recent market data indicates a trailing P/E around ~25x as of Aug 21, 2026 (USD listing), while analyst consensus remains broadly constructive (consensus “Buy” and average price targets in the mid-$200s per aggregators). (financecharts.com) For EUR context, Oracle’s Xetra line has recently traded around ~€125–€126 (delayed quotes). (in.marketscreener.com) Short- to medium-term outlook: revenue and operating income trends are supported by cloud demand and RPO visibility, but equity performance will likely be driven by (1) evidence that OCI capacity additions translate into recognized revenue on schedule, and (2) a credible path from negative FCF back toward sustainably positive FCF as capex intensity normalizes. (oracle.com)

Key Takeaways

Oracle’s growth narrative is now primarily OCI + cloud applications; management is guiding for very high cloud revenue growth rates near-term. (oracle.com)
RPO reached $638B (+363% YoY), providing unusually strong contracted-demand visibility but also raising execution/capacity-delivery expectations. (investor.oracle.com)
Profitability at the operating line improved (Q4 GAAP operating income +20%; non-GAAP operating income +22%), indicating operating discipline even during rapid scaling. (investor.oracle.com)
Cash flow is the central risk: FY2026 free cash flow was -$23.7B due to capex of $55.7B tied to data center expansion. (d18rn0p25nwr6d.cloudfront.net)
EUR investors should separate business performance from FX translation; the Xetra line has recently traded around ~€125–€126 (delayed), while most valuation commentary is anchored to the USD listing. (in.marketscreener.com)

Action Ideas

BUY

Accumulate on the view that the $638B RPO and management’s high cloud-growth guidance translate into multi-year revenue compounding, with operating income scaling as cloud mix rises. The data points supporting this are (a) record Q4/FY2026 results driven by cloud, (b) strong operating income growth, and (c) unusually large contracted backlog that can support sustained delivery if capacity ramps as planned. This is appropriate only for investors comfortable underwriting a capex-heavy transition period.

Horizon: 18 mo.

HOLD

Maintain exposure but require clearer evidence of cash flow inflection. The operating line is improving and cloud growth guidance is strong, but the investment case is currently constrained by capex intensity and negative FCF. A HOLD stance fits investors who want confirmation that capex-to-revenue and capex-to-operating-cash-flow ratios are trending down while cloud growth remains elevated.

Horizon: 12 mo.

SELL

Reduce exposure if your mandate prioritizes near-term free cash flow and balance-sheet conservatism. Oracle’s current phase is characterized by very large infrastructure investment and negative FCF, which can be incompatible with stricter cash-yield or dividend-growth frameworks. This action is driven by the documented FY2026 cash flow profile rather than a view on long-term cloud demand.

Horizon: 6 mo.

Contrarian Insights

• The headline $638B RPO is supportive, but it can also be interpreted as a capacity constraint signal: Oracle may be selling long-dated commitments faster than it can deliver near-term revenue, which can keep capex elevated and delay free-cash-flow normalization. (d18rn0p25nwr6d.cloudfront.net)
• Operating income strength can coexist with weak equity outcomes if per-share economics are diluted by funding needs during the build-out (debt/equity raises) and if investors re-price the stock toward cash-flow-based metrics rather than earnings-based metrics. (faircurve.io)